Alpha Tau Medical (DRTS) Projected to Post Quarterly Earnings on Wednesday

Alpha Tau Medical (NASDAQ:DRTS) is expected to post its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Alpha Tau Medical to post earnings of ($0.13) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Alpha Tau Medical Stock Performance

Shares of NASDAQ DRTS opened at $7.07 on Wednesday. The company has a market capitalization of $599.68 million, a P/E ratio of -13.60 and a beta of 1.02. Alpha Tau Medical has a 52-week low of $2.30 and a 52-week high of $8.60. The company’s 50 day moving average price is $6.80 and its 200-day moving average price is $4.97.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Wednesday, January 21st. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, Citigroup reduced their price objective on shares of Alpha Tau Medical from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alpha Tau Medical currently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Investors Weigh In On Alpha Tau Medical

Hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the third quarter valued at approximately $62,000. Bank of America Corp DE grew its position in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN increased its stake in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Millennium Management LLC bought a new stake in Alpha Tau Medical during the 3rd quarter valued at $170,000. Finally, Mariner LLC raised its holdings in Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after buying an additional 80,129 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.